Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis | Zendy

Andrea Chiricozzi | Zendy; Antonio Costanzo | Zendy; Maria Concetta Fargnoli | Zendy; Piergiorgio Malagoli | Zendy; Stefano Piaserico | Zendy; Paolo Amerio | Zendy; Giuseppe Argenziano | Zendy; Nicola Balato | Zendy; Federico Bardazzi | Zendy; Luca Bianchi | Zendy; Carlo Giovanni Carrera | Zendy; Andrea Conti | Zendy; Paolo Dapavo | Zendy; Clara De Simone | Zendy; Francesco Loconsole | Zendy; Ada Lo Schiavo | Zendy; Giovanna Malara | Zendy; Maria Letizia Musumeci | Zendy; Aurora Parodi | Zendy; Ketty Peris | Zendy; Francesca Prignano | Zendy; Franco Rongioletti | Zendy; Mark S. Talamonti | Zendy; Concetta Potenza | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Author(s) -

Andrea Chiricozzi,

Antonio Costanzo,

Maria Concetta Fargnoli,

Piergiorgio Malagoli,

Stefano Piaserico,

Paolo Amerio,

Giuseppe Argenziano,

Nicola Balato,

Federico Bardazzi,

Luca Bianchi,

Carlo Giovanni Carrera,

Andrea Conti,

Paolo Dapavo,

Clara De Simone,

Francesco Loconsole,

Ada Lo Schiavo,

Giovanna Malara,

Maria Letizia Musumeci,

Aurora Parodi,

Ketty Peris,

Francesca Prignano,

Franco Rongioletti,

Mark S. Talamonti,

Concetta Potenza

Publication year - 2021

Publication title -

european journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.48

H-Index - 71

eISSN - 1952-4013

pISSN - 1167-1122

DOI - 10.1684/ejd.2021.3965

Subject(s) - medicine , ustekinumab , psoriasis , dermatology , psoriatic arthritis , secukinumab , interleukin 23 , tolerability , clinical trial , psoriasis area and severity index , adalimumab , immunology , disease , adverse effect , immune system , interleukin 17

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research